ECSP11005642A - Nuevos pirazolopirimidinas como inhibidores de quinasa dependientes de ciclinas - Google Patents

Nuevos pirazolopirimidinas como inhibidores de quinasa dependientes de ciclinas

Info

Publication number
ECSP11005642A
ECSP11005642A EC2011005642A ECSP11005642A ECSP11005642A EC SP11005642 A ECSP11005642 A EC SP11005642A EC 2011005642 A EC2011005642 A EC 2011005642A EC SP11005642 A ECSP11005642 A EC SP11005642A EC SP11005642 A ECSP11005642 A EC SP11005642A
Authority
EC
Ecuador
Prior art keywords
compounds
pirazolopirimidinas
new
inhibitors
methods
Prior art date
Application number
EC2011005642A
Other languages
English (en)
Inventor
Timothy J Guzi
Ronald J Doll
Viyyoor Moopil Girijavallabhan
Kartik M Keertikar
Ray A James
Michael Dwyer
Alan Mallams
Carmen S Alvarez
Jocelyn Rivera
Tin Yau Chan
Vincent Madison
Thierry O Fischmann
Lawrence W Dillard
Vinh D Tran
Zhenmin He
Haengsoon Park
Vidyadhar M Paradkar
Kamil Paruch
Douglas Walsh Hobbs
Original Assignee
Schering Corp
Pharmacopeia Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp, Pharmacopeia Llc filed Critical Schering Corp
Publication of ECSP11005642A publication Critical patent/ECSP11005642A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En sus muchas realizaciones, la presente invención provee una nueva clase de compuestos de pirazolo [1,5-a] pirimidina como inhibidores de las quinasas dependientes de ciclina, métodos para preparar dichos compuestos, composiciones farmacéuticas que contienen uno o más de dichos compuestos, métodos para la preparación de formulaciones farmacéuticas que comprenden uno o más de dichos compuestos, y métodos para el tratamiento, prevención, inhibición, o mejoría de una o más enfermedades asociadas con las CDK usando dichos compuestos o composiciones farmacéuticas.
EC2011005642A 2002-09-04 2011-09-01 Nuevos pirazolopirimidinas como inhibidores de quinasa dependientes de ciclinas ECSP11005642A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40802702P 2002-09-04 2002-09-04
US42195902P 2002-10-29 2002-10-29

Publications (1)

Publication Number Publication Date
ECSP11005642A true ECSP11005642A (es) 2011-10-31

Family

ID=31981560

Family Applications (2)

Application Number Title Priority Date Filing Date
EC2005005642A ECSP055642A (es) 2002-09-04 2005-03-03 Nuevos pirazolopirimidinas como inhibidores de quinasa dependientes de ciclinas
EC2011005642A ECSP11005642A (es) 2002-09-04 2011-09-01 Nuevos pirazolopirimidinas como inhibidores de quinasa dependientes de ciclinas

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EC2005005642A ECSP055642A (es) 2002-09-04 2005-03-03 Nuevos pirazolopirimidinas como inhibidores de quinasa dependientes de ciclinas

Country Status (12)

Country Link
EP (1) EP2194058B1 (es)
JP (1) JP2010180234A (es)
AR (1) AR041137A1 (es)
CY (1) CY1110666T1 (es)
DE (1) DE60332846D1 (es)
EC (2) ECSP055642A (es)
ES (1) ES2346204T3 (es)
MY (1) MY138201A (es)
PL (1) PL224879B1 (es)
PT (1) PT1537116E (es)
RU (1) RU2380369C9 (es)
TW (1) TWI344468B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2713722B1 (en) 2011-05-31 2017-03-15 Receptos, LLC Novel glp-1 receptor stabilizers and modulators
BR112015031040A8 (pt) 2013-06-11 2018-01-02 Receptos Inc Novos moduladores do receptor de glp-1
CA2969944A1 (en) 2014-12-10 2016-06-16 Celgene International Ii Sarl Glp-1 receptor modulators
CA2995997A1 (en) 2015-08-26 2017-03-02 Blueprint Medicines Corporation Compounds and compositions useful for treating disorders related to ntrk
MX2018006195A (es) 2015-11-19 2018-09-05 Blueprint Medicines Corp Compuestos y composiciones utiles para el tratamiento de trastornos relacionados con ntrk.
CN116570594A (zh) 2016-06-23 2023-08-11 马里兰大学巴尔的摩分校 选择性p38α特异性MAPK抑制剂
MX2021006731A (es) * 2018-12-07 2021-09-23 Univ Maryland Inhibidores de proteínas quinasas activadas por mitógeno p38 en sitio no atp/catalítico.
EP4153303A1 (en) 2020-05-18 2023-03-29 GEN1E Lifesciences Inc. P38alpha mitogen-activated protein kinase inhibitors
EP4237415A1 (en) 2020-10-29 2023-09-06 GEN1E Lifesciences Inc. Crystalline 5-(dimethylamino)-n-(4-(morpholinomethyl)phenyl) naphthalene-1-sulfonamide di-hydrochloride di-hydrate
JP7659650B2 (ja) 2021-03-23 2025-04-09 ジーニー ライフサイエンシズ インコーポレイテッド 置換ナフチルｐ３８アルファマイトジェン活性化プロテインキナーゼ阻害剤
CN116983313B (zh) * 2023-07-13 2026-01-27 四川大学 Nu6300的新用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3907799A (en) 1971-08-16 1975-09-23 Icn Pharmaceuticals Xanthine oxidase inhibitors
JPH05507702A (ja) 1990-05-30 1993-11-04 アメリカン・ホーム・プロダクツ・コーポレイション 置換アリールスルホンアミド類およびベンズアミド類
WO1992018504A1 (en) 1991-04-22 1992-10-29 Otsuka Pharmaceutical Factory, Inc. PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVE AND ANTI-INFLAMMATORY CONTAINING THE SAME
US5571813A (en) 1993-06-10 1996-11-05 Beiersdorf-Lilly Gmbh Fused pyrimidine compounds and their use as pharmaceuticals
EP0628559B1 (en) * 1993-06-10 2002-04-03 Beiersdorf-Lilly GmbH Pyrimidine compounds and their use as pharmaceuticals
KR100315837B1 (ko) 1994-06-21 2002-02-28 고리 히데아끼 피라졸로[1,5-a]피리미딘유도체
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
DE69837282T2 (de) 1997-12-13 2007-11-08 Bristol-Myers Squibb Co. VERWENDUNG VON PYRAZOLO Ä 3,4-bÜ PYRIDIN ALS CYCLIN-ABHÄNGIGE KINASE HEMMER
US6413974B1 (en) * 1998-02-26 2002-07-02 Aventis Pharmaceuticals Inc. 6,9,-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines
US6194410B1 (en) * 1998-03-11 2001-02-27 Hoffman-La Roche Inc. Pyrazolopyrimidine and pyrazolines and process for preparation thereof
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DK0997474T3 (da) 1998-08-14 2004-02-09 Pfizer Antithrombotiske midler
AU752186B2 (en) 1998-10-30 2002-09-12 Merck & Co., Inc. Thrombin inhibitors
AU2795000A (en) 1998-12-22 2000-07-12 Novartis Ag Epothilone derivatives and their use as antitumor agents
DK1140938T3 (da) 1999-01-11 2003-12-22 Univ Princeton Højaffinitetsinhibitorer for målvalidering og anvendelser heraf
EP1196411B1 (en) 1999-07-15 2003-09-17 Pharmacopeia, Inc. Bradykinin b1 receptor antagonists
CN100457753C (zh) 2000-07-26 2009-02-04 布里斯托尔-迈尔斯斯奎布公司 依赖细胞周期蛋白的激酶的n－[5－[[[5－烷基－2－唑基]甲基]硫代]－2－噻唑基]甲酰胺抑制剂
EP1317453B1 (en) 2000-09-15 2006-08-09 Vertex Pharmaceuticals Incorporated Isoxazoles and their use as inhibitors of erk
PE20020507A1 (es) 2000-10-17 2002-06-25 Schering Corp Compuestos no-imidazoles como antagonistas del receptor histamina h3
US7067520B2 (en) 2000-11-17 2006-06-27 Ishihara Sangyo Kaisha, Ltd. Preventive or therapeutic medicines for diabetes containing fused-heterocyclic compounds or their salts
CA2432417A1 (fr) * 2000-12-20 2002-06-27 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R .A.S.) Inhibiteurs de kinases dependantes des cylines (cdk) et de la glycogene synthase kinase-3 (gsk-3)
WO2002064211A1 (en) 2001-02-09 2002-08-22 Merck & Co., Inc. Thrombin inhibitors

Also Published As

Publication number Publication date
TWI344468B (en) 2011-07-01
ES2346204T3 (es) 2010-10-13
DE60332846D1 (de) 2010-07-15
MY138201A (en) 2009-05-29
PT1537116E (pt) 2010-09-03
EP2194058B1 (en) 2013-11-27
JP2010180234A (ja) 2010-08-19
PL224879B1 (pl) 2017-02-28
TW200410973A (en) 2004-07-01
PL375697A1 (en) 2005-12-12
RU2380369C2 (ru) 2010-01-27
AR041137A1 (es) 2005-05-04
EP2194058A1 (en) 2010-06-09
CY1110666T1 (el) 2015-06-11
RU2005109543A (ru) 2006-05-10
RU2380369C9 (ru) 2011-07-10
ECSP055642A (es) 2005-05-30

Similar Documents

Publication Publication Date Title
ECSP088345A (es) Nuevas pirazolopirimidinas como inhibidores de quinasa dependientes de ciclina
ECSP088350A (es) Pirazolopirimidinas como inhibidores de protein quinasas
BRPI0314001B8 (pt) pirazolopirimidinas como inibidores de cinase dependente de ciclina e composição farmacêutica compreendendo as mesmas
MY149044A (en) Pyrazolopyrimidines - derivatives as cyclin dependent kinase inhibitors
MY137843A (en) Pyrazolopyrimidines as cyclin dependent kinase inhibitors
TW200420564A (en) Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
MX2009011355A (es) Nuevas pirazolopirimidinas como inhibidores de quinasas dependientes de ciclinas.
MY139336A (en) N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors
DE602006014848D1 (de) Pyrazolopyrimidine als inhibitoren von cyclinabhän
MX2009003733A (es) Pirazolopirimidinas como inhibidores de quinasas dependientes de ciclina.
ECSP066763A (es) Pirazolopirimidinas novedosas como inhibidores de quinasa ciclina-dependientes
MY134589A (en) Imidazopyrazines as cyclin dependent kinase inhibitors
MX2009003734A (es) Pirazolopirimidinas como inhibidor de cinasas dependientes de ciclina.
ECSP088906A (es) PIRAZOLO 1,5-a PIRIMIDINAS
ECSP088440A (es) Imidazopirazinas como inhibidores de proteinquinasa
TW200745128A (en) Pyrazolopyrimidines as protein kinase inhibitors
MY133311A (en) Novel imidazopyridines as cyclin dependent kinase inhibitors
MXPA05012573A (es) Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de cinasa.
UY27714A1 (es) 2 - heteroaril - pirimidinas inhibidoras de cdk, su preparación y su uso como medicamentos.
CO5271715A1 (es) 7-aza-indolin-2-onas sustituidas en 4 y su uso como inhibidores de proteiuna quinasa
TW200745127A (en) Pyrazolopyrimidines as protein kinase inhibitors
WO2004078682A3 (en) Cyclic compounds and compositions as protein kinase inhibitors
WO2007044401A3 (en) Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
WO2008045267A3 (en) Pyrazolopyrimidines as cyclin dependent kinase inhibitors
CY1110666T1 (el) Πυραζολοπυριμιδινες καταλληλες για θεραπεια καρκινικων νοσων